Rebecca Frey is Cardurion’s consulting chief operating officer. She began working as a member of Cardurion’s executive team in 2018 and transitioned to a consulting capacity in 2020. During her tenure, Rebecca has overseen most aspects of Cardurion operations, including drug development and manufacturing, across the portfolio. Rebecca has two decades of leadership experience in small and large biopharma, spanning drug development, medical affairs, M&A, manufacturing and real estate. She currently serves as chief operating officer of EvolveImmune Therapeutics and is a member of the board of directors of Halda Therapeutics.